NextCure reports NC318 37% DCR, 5.0 mo median PFS; NC410 safe in Ph1

NextCure, Inc.

NC318 Phase 1/2: 37% disease control rate, median PFS 5.0 mo across all tumors; lung cohort 45% DCR, median PFS 5.2 mo.
Two NSCLC patients on NC318 >2 years: one CR at 2.8 years, one PR at 2.2 years.
Modeling predicts 800 mg weekly NC318 yields ~10x exposure; sS15 may be biomarker for patient selection.
NC410 Ph1 (n=19) up to 60 mg Q2W: no dose-limiting toxicities; shows target binding, immune modulation, ECM remodeling.
Non-clinical data: NC410 synergizes with bintrafusp alpha (TGF-β trap) for tumor control in colon cancer model.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.